Abstract 19285: Vitamin D Influences Biomarkers of Oxidative Stress and Serum High Sensitivity C-Reactive Protein Concentrations: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Introduction: The effects of vitamin D (VitD) supplementation on health have been intensively investigated in recent years, but data on changes of oxidative stress parameters and serum high-sensitivity C-reactive protein (hs-CRP) concentrations following VitD supplementation are not completely known.
Hypothesis: We aimed to investigate the effect of VitD supplementation on serum hs-CRP concentrations and biomarkers of oxidative stress: [total antioxidant capacity (TAC), glutathione (GSH), malondialdehyde (MDA), nitric oxide (NO)] through systematic review and meta-analysis of available randomized controlled trials (RCTs).
Methods: We searched PubMed-Medline, SCOPUS, Web of Science and Google Scholar databases up to June 1, 2016. Overall, the impact of VitD versus control on plasma levels of TAC, GSH, MDA, hs-CRP and NO were assessed in 10 (12 treatment arms), 8 (10 treatment arms), 7 (9 treatment arms), 10 (12 treatment arms) and 5 (7 treatment arms) studies, respectively.
Results: Meta-analysis suggested that VitD supplementation conferred a significant increase in plasma TAC (standard mean difference [SMD]: 0.62, 95% confidence interval [CI]: 0.33, 0.90, p<0.001) (figure) and GSH (weighted mean difference [WMD]: 109.19 μmol/L, 95%CI: 34.30, 184.07, p=0.004) levels and reduction in MDA (WMD: -0.77 μmol/L, 95%CI: -1.09, -0.46, p<0.001), hs-CRP (WMD: -0.62 mg/L, 95%CI: -1.07, -0.17, p=0.007) and NO (WMD: -4.14 μmol/L, 95%CI: -7.05, -1.22, p=0.005) levels. Duration of VitD supplementation was not associated with changes in plasma levels of the assessed parameters (TAC, GSH, MDA, hs-CRP and NO).
Conclusion: Our meta-analysis found a generally favorable influence on markers of oxidative stress and inflammation with Vitamin D treatment. Further well-designed trials are necessary to validate these results and explain their clinical relevance.
Author Disclosures: M. Serban: None. A. Sahebkar: None. E.D. Michos: None. P.J. Barter: None. P. Muntner: None. P.P. Toth: Speakers Bureau; Modest; Kowa, Novartis, Sanofi-Aventis. Speakers Bureau; Significant; Amarin, Amgen, Merck, Regeneron. Consultant/Advisory Board; Modest; Merck, Regeneron, Sanofi-Aventis. Consultant/Advisory Board; Significant; Amgen, Kowa, Regeneron, Merck. S.S. Martin: None. M.J. Blaha: None. J. Rysz: None. S.R. Jones: None. D.P. Mikhailidis: None. M. Banach: None.
- © 2016 by American Heart Association, Inc.